ASTRANA HEALTH INC (ASTH) Stock Fundamental Analysis
NASDAQ:ASTH - Nasdaq - US03763A2078 - Common Stock - Currency: USD
We assign a fundamental rating of 5 out of 10 to ASTH. ASTH was compared to 102 industry peers in the Health Care Providers & Services industry. Both the profitability and the financial health of ASTH get a neutral evaluation. Nothing too spectacular is happening here. ASTH is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year ASTH was profitable.
ASTH had a positive operating cash flow in the past year.
Each year in the past 5 years ASTH has been profitable.
ASTH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of 3.18%, ASTH is doing good in the industry, outperforming 65.69% of the companies in the same industry.
Looking at the Return On Equity, with a value of 6.05%, ASTH is in the better half of the industry, outperforming 61.76% of the companies in the same industry.
ASTH's Return On Invested Capital of 5.70% is fine compared to the rest of the industry. ASTH outperforms 61.76% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ASTH is below the industry average of 9.53%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.18% | ||
| ROE | 6.05% | ||
| ROIC | 5.7% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
1.3 Margins
ASTH's Profit Margin of 2.12% is fine compared to the rest of the industry. ASTH outperforms 61.76% of its industry peers.
ASTH's Profit Margin has declined in the last couple of years.
ASTH has a Operating Margin of 4.39%. This is comparable to the rest of the industry: ASTH outperforms 56.86% of its industry peers.
In the last couple of years the Operating Margin of ASTH has declined.
ASTH has a worse Gross Margin (13.34%) than 71.57% of its industry peers.
In the last couple of years the Gross Margin of ASTH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.39% | ||
| PM (TTM) | 2.12% | ||
| GM | 13.34% |
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ASTH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ASTH has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, ASTH has a worse debt to assets ratio.
2.2 Solvency
ASTH has an Altman-Z score of 3.58. This indicates that ASTH is financially healthy and has little risk of bankruptcy at the moment.
ASTH has a Altman-Z score of 3.58. This is in the better half of the industry: ASTH outperforms 73.53% of its industry peers.
The Debt to FCF ratio of ASTH is 9.87, which is on the high side as it means it would take ASTH, 9.87 years of fcf income to pay off all of its debts.
ASTH has a Debt to FCF ratio (9.87) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.60 indicates that ASTH is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.60, ASTH perfoms like the industry average, outperforming 57.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | 9.87 | ||
| Altman-Z | 3.58 |
ROIC/WACC0.68
WACC8.42%
2.3 Liquidity
ASTH has a Current Ratio of 1.75. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ASTH (1.75) is better than 63.73% of its industry peers.
ASTH has a Quick Ratio of 1.75. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
ASTH has a Quick ratio of 1.75. This is in the better half of the industry: ASTH outperforms 67.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.75 | ||
| Quick Ratio | 1.75 |
3. Growth
3.1 Past
The earnings per share for ASTH have decreased strongly by -45.45% in the last year.
The Earnings Per Share has been growing by 19.19% on average over the past years. This is quite good.
The Revenue has grown by 46.72% in the past year. This is a very strong growth!
ASTH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 38.01% yearly.
EPS 1Y (TTM)-45.45%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-54.84%
Revenue 1Y (TTM)46.72%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%53.43%
3.2 Future
ASTH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.87% yearly.
Based on estimates for the next years, ASTH will show a quite strong growth in Revenue. The Revenue will grow by 16.54% on average per year.
EPS Next Y40.34%
EPS Next 2Y35.27%
EPS Next 3Y41.54%
EPS Next 5Y31.87%
Revenue Next Year36.43%
Revenue Next 2Y28.34%
Revenue Next 3Y25.22%
Revenue Next 5Y16.54%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 33.99, the valuation of ASTH can be described as expensive.
ASTH's Price/Earnings is on the same level as the industry average.
ASTH is valuated rather expensively when we compare the Price/Earnings ratio to 25.91, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 15.03, which indicates a correct valuation of ASTH.
75.49% of the companies in the same industry are more expensive than ASTH, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.85, ASTH is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.99 | ||
| Fwd PE | 15.03 |
4.2 Price Multiples
ASTH's Enterprise Value to EBITDA is on the same level as the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ASTH is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.06 | ||
| EV/EBITDA | 13.26 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ASTH's earnings are expected to grow with 41.54% in the coming years.
PEG (NY)0.84
PEG (5Y)1.77
EPS Next 2Y35.27%
EPS Next 3Y41.54%
5. Dividend
5.1 Amount
ASTH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
24.47
-0.72 (-2.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners47.59%
Inst Owner ChangeN/A
Ins Owners8.89%
Ins Owner Change-10.53%
Market Cap1.37B
Analysts83.33
Price Target51.51 (110.5%)
Short Float %3.55%
Short Ratio4.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.09
Dividend Growth(5Y)N/A
DP9.35%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-111.71%
Min EPS beat(2)-225.16%
Max EPS beat(2)1.74%
EPS beat(4)3
Avg EPS beat(4)-55.53%
Min EPS beat(4)-225.16%
Max EPS beat(4)1.74%
EPS beat(8)6
Avg EPS beat(8)-12.72%
EPS beat(12)9
Avg EPS beat(12)1.75%
EPS beat(16)13
Avg EPS beat(16)12.21%
Revenue beat(2)2
Avg Revenue beat(2)3.58%
Min Revenue beat(2)1.5%
Max Revenue beat(2)5.66%
Revenue beat(4)3
Avg Revenue beat(4)2.78%
Min Revenue beat(4)-4.21%
Max Revenue beat(4)8.16%
Revenue beat(8)5
Avg Revenue beat(8)1.73%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.7%
PT rev (3m)-18.68%
EPS NQ rev (1m)-6.32%
EPS NQ rev (3m)-27.41%
EPS NY rev (1m)-7.18%
EPS NY rev (3m)-13.66%
Revenue NQ rev (1m)0.28%
Revenue NQ rev (3m)3%
Revenue NY rev (1m)-0.14%
Revenue NY rev (3m)1.62%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.99 | ||
| Fwd PE | 15.03 | ||
| P/S | 0.67 | ||
| P/FCF | 31.06 | ||
| P/OCF | 26.29 | ||
| P/B | 1.93 | ||
| P/tB | 7.83 | ||
| EV/EBITDA | 13.26 |
EPS(TTM)0.72
EY2.94%
EPS(NY)1.63
Fwd EY6.66%
FCF(TTM)0.79
FCFY3.22%
OCF(TTM)0.93
OCFY3.8%
SpS36.29
BVpS12.71
TBVpS3.13
PEG (NY)0.84
PEG (5Y)1.77
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.18% | ||
| ROE | 6.05% | ||
| ROCE | 9.03% | ||
| ROIC | 5.7% | ||
| ROICexc | 8.07% | ||
| ROICexgc | 35.01% | ||
| OM | 4.39% | ||
| PM (TTM) | 2.12% | ||
| GM | 13.34% | ||
| FCFM | 2.17% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ROICexc(3y)11.13%
ROICexc(5y)11.73%
ROICexgc(3y)50.18%
ROICexgc(5y)49.73%
ROCE(3y)11.21%
ROCE(5y)11.68%
ROICexcg growth 3Y-13.47%
ROICexcg growth 5YN/A
ROICexc growth 3Y-16.27%
ROICexc growth 5YN/A
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
F-Score4
Asset Turnover1.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | 9.87 | ||
| Debt/EBITDA | 3.63 | ||
| Cap/Depr | 28.76% | ||
| Cap/Sales | 0.39% | ||
| Interest Coverage | 2.94 | ||
| Cash Conversion | 44.51% | ||
| Profit Quality | 102.36% | ||
| Current Ratio | 1.75 | ||
| Quick Ratio | 1.75 | ||
| Altman-Z | 3.58 |
F-Score4
WACC8.42%
ROIC/WACC0.68
Cap/Depr(3y)106.76%
Cap/Depr(5y)87.27%
Cap/Sales(3y)1.49%
Cap/Sales(5y)1.42%
Profit Quality(3y)99.59%
Profit Quality(5y)98.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-45.45%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-54.84%
EPS Next Y40.34%
EPS Next 2Y35.27%
EPS Next 3Y41.54%
EPS Next 5Y31.87%
Revenue 1Y (TTM)46.72%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%53.43%
Revenue Next Year36.43%
Revenue Next 2Y28.34%
Revenue Next 3Y25.22%
Revenue Next 5Y16.54%
EBIT growth 1Y5.59%
EBIT growth 3Y-3.09%
EBIT growth 5YN/A
EBIT Next Year82.75%
EBIT Next 3Y45.19%
EBIT Next 5Y30.92%
FCF growth 1Y11.26%
FCF growth 3Y-4.75%
FCF growth 5YN/A
OCF growth 1Y-23.49%
OCF growth 3Y-9.46%
OCF growth 5YN/A